8,217 Shares in Revolution Medicines, Inc. $RVMD Acquired by Lido Advisors LLC

Lido Advisors LLC bought a new stake in shares of Revolution Medicines, Inc. (NASDAQ:RVMD – Free Report) in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 8,217 shares of the company’s stock, valued at approximately $1,687,000.

Several other large investors have also recently made changes to their positions in RVMD. Bluestem Financial Advisors LLC boosted its holdings in Revolution Medicines by 4.8% during the third quarter. Bluestem Financial Advisors LLC now owns 1,256 shares of the company’s stock worth $258,000 after buying an additional 58 shares in the last quarter. IFP Advisors Inc increased its holdings in Revolution Medicines by 8.7% in the third quarter. IFP Advisors Inc now owns 810 shares of the company’s stock valued at $166,000 after buying an additional 65 shares in the last quarter. Brighton Jones LLC increased its holdings in Revolution Medicines by 2.9% in the third quarter. Brighton Jones LLC now owns 3,565 shares of the company’s stock valued at $732,000 after buying an additional 99 shares in the last quarter. TD Waterhouse Canada Inc. increased its holdings in Revolution Medicines by 37.0% in the third quarter. TD Waterhouse Canada Inc. now owns 370 shares of the company’s stock valued at $76,000 after buying an additional 100 shares in the last quarter. Finally, Meeder Advisory Services Inc. raised its position in shares of Revolution Medicines by 3.0% in the first quarter. Meeder Advisory Services Inc. now owns 4,126 shares of the company’s stock worth $401,000 after acquiring an additional 120 shares during the period. 94.34% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Revolution Medicines

In other news, Director Elizabeth Anderson sold 10,143 shares of the business’s stock in a transaction dated Tuesday, September 22nd. The shares were sold at an average price of $193.04, for a total transaction of $1,958,004.72. Following the completion of the sale, the director owned 4,333 shares of the company’s stock, valued at $836,442.32. The trade was a 70.07% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, COO Margaret Horn sold 4,967 shares of the company’s stock in a transaction dated Wednesday, September 16th. The stock was sold at an average price of $199.24, for a total transaction of $989,625.08. Following the transaction, the chief operating officer owned 149,680 shares of the company’s stock, valued at approximately $29,822,243.20. This trade represents a 3.21% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last ninety days, insiders have sold 326,741 shares of company stock valued at $66,147,340. Corporate insiders own 7.60% of the company’s stock.

Revolution Medicines Price Performance

Revolution Medicines stock opened at $172.29 on Monday. The company’s fifty day moving average price is $194.46 and its 200 day moving average price is $159.42. Revolution Medicines, Inc. has a 1 year low of $63.50 and a 1 year high of $224.31. The stock has a market capitalization of $37.26 billion, a P/E ratio of -18.91 and a beta of 1.44. The company has a debt-to-equity ratio of 0.44, a quick ratio of 8.34 and a current ratio of 8.36.

Revolution Medicines (NASDAQ:RVMD – Get Free Report) last issued its quarterly earnings results on Wednesday, November 4th. The company reported ($1.90) EPS for the quarter, topping the consensus estimate of ($2.35) by $0.45. The company had revenue of $197.56 million during the quarter, compared to analysts’ expectations of $25.58 million. During the same period in the previous year, the firm posted ($1.61) EPS. As a group, equities research analysts anticipate that Revolution Medicines, Inc. will post -7.41 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research analysts have weighed in on the stock. Needham & Company LLC reiterated a “buy” rating and issued a $275.00 price objective on shares of Revolution Medicines in a research report on Thursday, October 15th. Royal Bank Of Canada raised their target price on Revolution Medicines from $260.00 to $321.00 and gave the company an “outperform” rating in a research report on Thursday, November 5th. Sanford C. Bernstein raised their target price on Revolution Medicines from $151.00 to $179.00 and gave the company a “market perform” rating in a research report on Friday, August 21st. Evercore restated an “outperform” rating and issued a $320.00 price target on shares of Revolution Medicines in a research note on Thursday, August 27th. Finally, Wolfe Research reaffirmed an “outperform” rating and issued a $220.00 price target on shares of Revolution Medicines in a report on Monday, August 10th. One research analyst has rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $262.75.

View Our Latest Stock Report on Revolution Medicines

About Revolution Medicines

(Free Report)

Revolution Medicines, Inc. is a biotechnology company focused on developing targeted therapies for patients with RAS-driven cancers. Founded in 2014 and headquartered in Redwood City, California, the company’s research centers on RAS proteins, which can contribute to the growth of many cancers. The company’s pipeline includes drug candidates designed to inhibit mutant RAS proteins, including daraxonrasib (RMC-6236), which targets multiple RAS variants, and candidates directed at specific KRAS mutations.

Read More

Want to see what other hedge funds are holding RVMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Revolution Medicines, Inc. (NASDAQ:RVMD – Free Report).

Institutional Ownership by Quarter for Revolution Medicines (NASDAQ:RVMD)

Receive News & Ratings for Revolution Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revolution Medicines and related companies with MarketBeat.com's FREE daily email newsletter.